Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611752 · ClinicalTrials.gov registry record · Phase 2
A Multiple Dose Opioid Challenge Study
A Phase 2 study, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02611752 is a Phase 2 study that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT02611752, a Phase 2 study, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use disorder.
Interventions
- DRUG CAM2038
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611752
The ClinicalTrials.gov registry entry for NCT02611752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braeburn Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAM2038 is the first listed.
NCT02611752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611752 about?
NCT02611752 is a clinical study titled "A Multiple Dose Opioid Challenge Study". Multi-site, randomized, double-blind, repeat-dose Phase 2 study to evaluate the degree and duration of action of multiple doses of CAM2038 in blocking the effects of hydromorphone in patients with moderate or severe opioid use disorder.
What is the current status of trial NCT02611752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2015-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02611752?
The interventions under investigation include: CAM2038 (DRUG).
Who is sponsoring clinical trial NCT02611752?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.